---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-391280"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-09-15T10:45:34+00:00"
generated_at: "2026-09-15T10:50:15.340407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# TRUTAKNA meets all endpoints in ORIGIN 3 final analysis; stabilizes eGFR, cuts progression risk 76%

## Summary
- Mean eGFR change at 52 weeks: TRUTAKNA -0.1 vs placebo -5.7 mL/min/1.73m² (treatment effect 5.6, p<0.0001).
- Annualized eGFR slope to 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/yr (effect 5.0, p<0.0001).
- Composite kidney progression events: 11 vs 38; HR 0.24 (95% CI 0.12-0.48), 76% risk reduction (p<0.0001).
- No dialysis/transplant/death events in TRUTAKNA arm vs 8 on placebo through 104 weeks; safety comparable to placebo.
- Over 350 patient start forms in first 10 weeks of launch; sBLA for full FDA approval planned Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-391280
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-09-15T10:45:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/0001193125-26-391280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-391280
- JSON: https://secwatch.observer/filing/0001193125-26-391280.json
- Plain text: https://secwatch.observer/filing/0001193125-26-391280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.